February 21, 2018 / 1:50 PM / 3 months ago

BRIEF-Eyenovia Advances Micropine For Myopia Into Phase III Clinical Development

Feb 21 (Reuters) - Eyenovia Inc:

* EYENOVIA ADVANCES MICROPINE FOR MYOPIA INTO PHASE III CLINICAL DEVELOPMENT AND APPOINTS STANFORD PROFESSOR DR. DOUGLAS FREDRICK TO ITS SCIENTIFIC ADVISORY BOARD AND MYOPIA PROGRAM STEERING COMMITTEE

* EYENOVIA INC - MICROPINE PHASE III TRIAL FOR MYOPIA IS PLANNED TO START IN FIRST HALF OF 2019

* EYENOVIA INC - EYENOVIA HAS RECEIVED FEEDBACK THAT ONLY ONE PHASE III PIVOTAL STUDY WILL BE REQUIRED FOR REGISTRATION INSTEAD OF TWO TRIALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below